| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 25 | 2024 | 1079 | 2.100 |
Why?
|
| Cerebral Hemorrhage | 12 | 2024 | 158 | 1.660 |
Why?
|
| Brain Ischemia | 9 | 2022 | 278 | 0.950 |
Why?
|
| Telemedicine | 6 | 2024 | 507 | 0.700 |
Why?
|
| Kentucky | 15 | 2024 | 28 | 0.620 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1053 | 0.560 |
Why?
|
| Ohio | 13 | 2024 | 87 | 0.530 |
Why?
|
| Fibrinolytic Agents | 5 | 2022 | 209 | 0.360 |
Why?
|
| Health Status Disparities | 4 | 2024 | 251 | 0.350 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2022 | 121 | 0.330 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 71 | 0.330 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 416 | 0.320 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 70 | 0.310 |
Why?
|
| Hyperglycemia | 2 | 2014 | 242 | 0.310 |
Why?
|
| Sex Factors | 7 | 2020 | 1354 | 0.300 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 7197 | 0.300 |
Why?
|
| Veterans | 5 | 2024 | 1790 | 0.290 |
Why?
|
| Aged | 27 | 2024 | 21584 | 0.280 |
Why?
|
| Brain | 2 | 2012 | 3220 | 0.280 |
Why?
|
| Hypertension | 3 | 2024 | 1398 | 0.270 |
Why?
|
| Blood Pressure | 3 | 2024 | 1381 | 0.250 |
Why?
|
| Middle Aged | 25 | 2024 | 29081 | 0.240 |
Why?
|
| Mushroom Bodies | 1 | 2005 | 48 | 0.230 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 85 | 0.220 |
Why?
|
| Humans | 46 | 2024 | 133529 | 0.220 |
Why?
|
| Apolipoprotein E2 | 2 | 2014 | 15 | 0.210 |
Why?
|
| Migraine Disorders | 1 | 2024 | 66 | 0.210 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 883 | 0.210 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 8 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 124 | 0.200 |
Why?
|
| Male | 31 | 2024 | 65657 | 0.200 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 3 | 0.190 |
Why?
|
| Neurology | 1 | 2024 | 120 | 0.190 |
Why?
|
| Risk Factors | 12 | 2024 | 10970 | 0.190 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 245 | 0.190 |
Why?
|
| Axons | 1 | 2005 | 397 | 0.190 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 1166 | 0.190 |
Why?
|
| Endocarditis | 1 | 2023 | 107 | 0.180 |
Why?
|
| Incidence | 7 | 2024 | 3393 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 760 | 0.180 |
Why?
|
| Female | 29 | 2024 | 71560 | 0.170 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 236 | 0.170 |
Why?
|
| Cocaine | 1 | 2022 | 208 | 0.170 |
Why?
|
| Poverty | 1 | 2024 | 436 | 0.170 |
Why?
|
| Recurrence | 1 | 2024 | 1470 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 557 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 153 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 138 | 0.160 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 771 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 567 | 0.160 |
Why?
|
| Thrombolytic Therapy | 3 | 2022 | 214 | 0.150 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 3364 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 66 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2019 | 400 | 0.150 |
Why?
|
| Time Factors | 8 | 2024 | 6545 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1340 | 0.150 |
Why?
|
| Prospective Studies | 8 | 2017 | 6586 | 0.140 |
Why?
|
| Certification | 1 | 2019 | 72 | 0.140 |
Why?
|
| Case-Control Studies | 6 | 2016 | 3450 | 0.140 |
Why?
|
| Deprescriptions | 1 | 2017 | 12 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 493 | 0.140 |
Why?
|
| Cerebral Arteries | 1 | 2018 | 82 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 54 | 0.130 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 189 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 99 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 489 | 0.130 |
Why?
|
| Troponin | 1 | 2017 | 79 | 0.130 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 106 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 103 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 482 | 0.120 |
Why?
|
| Triage | 1 | 2017 | 148 | 0.120 |
Why?
|
| Prevalence | 5 | 2024 | 2678 | 0.120 |
Why?
|
| Epilepsy | 1 | 2024 | 899 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2024 | 17579 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 114 | 0.120 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Urban Population | 1 | 2017 | 244 | 0.120 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 84 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 46 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2018 | 381 | 0.120 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 78 | 0.120 |
Why?
|
| Neurons | 1 | 2005 | 2050 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 292 | 0.110 |
Why?
|
| Genotype | 4 | 2014 | 2715 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 198 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 699 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 150 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1347 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 518 | 0.100 |
Why?
|
| Warfarin | 1 | 2014 | 134 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 81 | 0.100 |
Why?
|
| White Matter | 1 | 2015 | 212 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 198 | 0.100 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 18 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2015 | 394 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 494 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 518 | 0.090 |
Why?
|
| Sleep | 1 | 2015 | 370 | 0.090 |
Why?
|
| Adult | 8 | 2024 | 31787 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 233 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2017 | 13101 | 0.090 |
Why?
|
| Echocardiography | 1 | 2017 | 1120 | 0.090 |
Why?
|
| United States | 6 | 2024 | 11761 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 863 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 677 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2012 | 249 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1840 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2649 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1468 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2024 | 715 | 0.070 |
Why?
|
| Phenotype | 1 | 2018 | 4581 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2956 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1418 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 573 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 114 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 93 | 0.060 |
Why?
|
| Headache Disorders | 1 | 2024 | 4 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 5205 | 0.060 |
Why?
|
| Larva | 1 | 2005 | 260 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 118 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 434 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2088 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 342 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 402 | 0.050 |
Why?
|
| Neurologists | 1 | 2024 | 27 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2005 | 222 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 288 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5453 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 1268 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 457 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 207 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 296 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 3097 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1870 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 244 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 237 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 165 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 19 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 323 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 367 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 36 | 0.040 |
Why?
|
| Occupational Health | 1 | 2021 | 48 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 156 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1049 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 36122 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1530 | 0.040 |
Why?
|
| Rats | 2 | 2018 | 3848 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 844 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1431 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 524 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 766 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 442 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 327 | 0.040 |
Why?
|
| Rats, Inbred BN | 1 | 2018 | 16 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 542 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 237 | 0.040 |
Why?
|
| Basilar Artery | 1 | 2018 | 25 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 471 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 131 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 103 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 200 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 520 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2021 | 409 | 0.030 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 11 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1591 | 0.030 |
Why?
|
| Halogenation | 1 | 2017 | 6 | 0.030 |
Why?
|
| Ventriculostomy | 1 | 2017 | 44 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2018 | 238 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 629 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 162 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 541 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 437 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 596 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4766 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2015 | 56 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 424 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 260 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 66 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 211 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 235 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2720 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 446 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 682 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 9980 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 627 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 12 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 4918 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1584 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1467 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 314 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 782 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2249 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 6332 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2880 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 774 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 804 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1179 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1654 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2190 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3758 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 5052 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 946 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2856 | 0.010 |
Why?
|
| Child | 1 | 2022 | 25888 | 0.010 |
Why?
|